AtriCure
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict AtriCure's revenues will expand 6.3% and EPS will remain in the red.
The average estimate for revenue is $19.4 million. On the bottom line, the average EPS estimate is -$0.10.
Revenue details
Last quarter, AtriCure booked revenue of $19.4 million. GAAP reported sales were 11% higher than the prior-year quarter's $17.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
Last quarter, EPS came in at -$0.10. GAAP EPS of -$0.10 were the same as the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Recent performance
For the preceding quarter, gross margin was 72.5%, 50 basis points worse than the prior-year quarter. Operating margin was -9.3%, 100 basis points worse than the prior-year quarter. Net margin was -10.0%, 70 basis points worse than the prior-year quarter.
Looking ahead
The full year's average estimate for revenue is $77.7 million. The average EPS estimate is -$0.40.
Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 43 members out of 49 rating the stock outperform, and six members rating it underperform. Among 11 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 10 give AtriCure a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AtriCure is outperform, with an average price target of $11.40.
Is AtriCure the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add AtriCure to My Watchlist.
